SCHEMBL182062

SCHEMBL182062

CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(Cn1c2nc(=O)[nH]c(=O)c-2nc2cc(C)c(C)cc21)OC(=O)CCC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 1.00
KMT2A Q03164 7/20 1.00
HTT P42858 4/20 1.00
HAT1 O14929 4/20 1.00
RBBP7 Q16576 4/20 1.00
KDM4E B2RXH2 5/20 0.54
USP2 O75604 4/20 0.54
MAPT P10636 4/20 0.54
TDP1 Q9NUW8 3/20 0.54
RXFP1 Q9HBX9 2/20 0.54
IDO1 P14902 1/20 0.54
RECQL P46063 3/20 0.52
CASP7 P55210 3/20 0.52
CASP1 P29466 2/20 0.52
BRCA1 P38398 2/20 0.52
HSD17B10 Q99714 2/20 0.52
TST Q16762 2/20 0.52
ALDH1A1 P00352 2/20 0.52
HPGD P15428 2/20 0.52
LMNA P02545 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30113081 1.00 MEN1 (1.00) MEN1KMT2AHTTHAT1RBBP7
SCHEMBL182061 1.00 MEN1 (1.00) MEN1KMT2AHTTHAT1RBBP7
SCHEMBL29940644 1.00 MEN1 (1.00) MEN1KMT2AHTTHAT1RBBP7
SCHEMBL22711765 1.00 MEN1 (1.00) MEN1KMT2AHTTHAT1RBBP7
SCHEMBL31029204 0.94 MEN1 (0.88) MEN1KMT2AHTTHAT1RBBP7
SCHEMBL31029243 0.91 MEN1 (0.84) MEN1KMT2AHTTHAT1RBBP7
SCHEMBL31029223 0.91 MEN1 (0.84) MEN1KMT2AHTTHAT1RBBP7
SCHEMBL19192224 0.90 MEN1 (0.82) MEN1KMT2AHTTHAT1RBBP7
SCHEMBL15908089 0.90 MEN1 (0.81) MEN1KMT2AHTTHAT1RBBP7
SCHEMBL15909982 0.89 MEN1 (0.80) MEN1KMT2AHTTHAT1RBBP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 598 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144875-A1 COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS ADS THERAPEUTICS LLC (US) 2026-05-28 US claimed
CN-122056386-A Moisture absorption resistant slow release microcapsule powder and preparation method and application thereof 大连医诺生物股份有限公司 2026-05-19 CN claimed
CN-122030612-A Shear-resistant slow-release microcapsule powder and preparation method and application thereof 大连医诺生物股份有限公司 2026-05-15 CN claimed
EP-4637775-A1 COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS ADS Therapeutics LLC (US) 2025-10-29 EP claimed
WO-2025131038-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF PHARMACEUTICAL ACTIVES ADS THERAPEUTICS LLC (US) 2025-06-26 WO claimed
US-20250188117-A1 C-Terminal Peptide Modification TECHNISCHE UNIVERSITEIT DELFT (NL) 2025-06-12 US claimed
US-12312605-B2 Riboflavin derivative-containing medium AJINOMOTO CO., INC. (JP) 2025-05-27 US claimed
CN-120004760-A Ultrasonic activated azido precursor, prodrug and application 中国科学院长春应用化学研究所 2025-05-16 CN claimed
CN-119185313-A Leishmod prodrug, and preparation method and application thereof 中国科学院长春应用化学研究所 2024-12-27 CN claimed
CN-118416861-A Preparation method and application of magnetic graphene oxide-flavin molecularly imprinted material 长江生态环保集团有限公司 2024-08-02 CN claimed
EP-0759750-A4 COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES SHAPIRO HOWARD K (US) 1998-05-27 EP claimed
EP-0759750-A1 COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES SHAPIRO, Howard, K. (US) 1997-03-05 EP claimed
EP-0739208-A1 FLAVIN DERIVATIVES AS ANTI-VIRAL AGENTS RADOPATH LIMITED (GB) 1996-10-30 EP claimed
WO-1995031194-A1 COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES SHAPIRO HOWARD K (US) 1995-11-23 WO claimed
WO-1995011028-A1 FLAVIN DERIVATIVES AS ANTI-VIRAL AGENTS RADOPATH LIMITED (GB) 1995-04-27 WO claimed
EP-0384366-B1 Photosensitive recording element BASF AG (DE) 1995-02-15 EP claimed
WO-1993010784-A1 THERAPEUTIC COMPOSITION AND METHOD FOR PREVENTING REPERFUSION INJURY UNIVERSITY OF MICHIGAN (US) 1993-06-10 WO claimed
US-5153236-A Comprising an N-aryl-alpha-amino acid and a photosensitizer such as a thixoanthone, isoalloxazine or coumarine; high sensitivity to UV and visible light; storage stability; photoresists; relief images HITACHI CHEMICAL CO., LTD. (JP) 1992-10-06 US claimed
US-5112723-A Relief images, printing plates, photoresists, alloxazine compounds BASF AKTIENGESELLSCHAFT (DE) 1992-05-12 US claimed
US-4407821-A LINOLENIC ACID OR ESTER, TRIGLYCERIDES ROUSSEL UCLAF (FR) 1983-10-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188117-A1 C-Terminal Peptide Modification PTMS, NGLY1, QPCT MEN1 276/4885KMT2A 3163/4885HTT 1309/4885
US-20260144875-A1 COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS STRA6, RBP4, F12 MEN1 4816/4885KMT2A 4211/4885HTT 2084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.